| NCT ID | NCT03870620 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Arbeitsgemeinschaft medikamentoese Tumortherapie |
| Condition | Breast Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,000 participants |
| Start Date | 2015-06-15 |
| Primary Completion | 2025-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,000 participants in total. It began in 2015-06-15 with a primary completion date of 2025-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Breast cancer is the most common cancer among women worldwide. In Austria, this diagnosis is made more than 5000 times a year (STATISTICS AUSTRIA, Austrian Cancer Registry, as of 24.09.2012). Of these, already 5% to 10% have distant metastases at the time of initial diagnosis, and up to 30% of the node-negative tumours and up to 70% of the node-positive tumours metastasise at a later date. Metastatic breast cancer has not been systematically assessed in Austria to date. This medical registry of the AGMT is thus the first Austrian-wide standardised documentation of this disease. The aim of the registry is to answer both epidemiological and therapy-specific questions. This registry is a prospective and retrospective, multicentre collection of data on patients with metastatic breast cancer in Austria. All tumour characteristics, medical histories and also treatment sequences are documented in anonymised form.
Eligibility Criteria
Inclusion Criteria: * Histological evidence of breast cancer * Histological and/or radiological evidence of metastases * Metastasis within 10 years of registry initiation * Signed informed consent (if a patient has already died at the time of entry, the entry can be made without a declaration of consent) Exclusion Criteria: * Due to the non-interventional design of the registry there are no specific exclusion criteria.
Contact & Investigator
Richard Greil, MD
STUDY CHAIR
AGMT gemeinnützige GmbH
Frequently Asked Questions
Who can join the NCT03870620 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03870620 currently recruiting?
Yes, NCT03870620 is actively recruiting participants. Contact the research team at d.wolkersdorfer@agmt.at for enrollment information.
Where is the NCT03870620 trial being conducted?
This trial is being conducted at Salzburg, Austria, Vienna, Austria, Graz, Austria, Innsbruck, Austria and 11 additional locations.
Who is sponsoring the NCT03870620 clinical trial?
NCT03870620 is sponsored by Arbeitsgemeinschaft medikamentoese Tumortherapie. The principal investigator is Richard Greil, MD at AGMT gemeinnützige GmbH. The trial plans to enroll 5,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.